Time‑Dependent Regulation of Apoptosis by AEN and BAX in Response to 2‑Aminoanthracene Dietary Consumption


  • Georgia Southern University, Department of Chemistry, Statesboro, Georgia
  • Southern Illinois University, Carbondale, School of Medicine, Department of Physiology, Carbondale
  • UC Santa Barbara, 2Bren School of Environmental Science and Management, Santa Barbara, California, United States


Background/Objective: The modulation of the toxic effects of 2-aminoanthracene (2AA) on the liver by apoptosis was investigated. Fisher-344 (F344) rats were exposed to various concentrations of 2AA for 14 and 28 days. The arylamine 2AA is an aromatic hydrocarbon employed in manufacturing chemicals, dyes, inks, and it is also a curing agent in epoxy resins and polyurethanes. 2AA has been detected in tobacco smoke and cooked foods. Methods: Analysis of total messenger ribonucleic acid (mRNA) extracts from liver for apoptosis-related gene expression changes in apoptosis enhancing nuclease (AEN), Bcl2-associated X protein (BAX), CASP3, Jun proto-oncogene (JUN), murine double minute-2 p53 binding protein homolog (MDM2), tumor protein p53 (p53), and GAPDH genes by quantitative real-time polymerase chain reaction (qRT-PCR) was coupled with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and caspase-3 (Casp3) activity assays. Results: Specific apoptosis staining result does not seem to show significant difference between control and treated animals. This may be due to freeze-thaw artifacts observed in the liver samples. However, there appears to be a greater level of apoptosis in medium- and high-dose (MD and HD) 2AA treated animals. Analyses of apoptosis-related genes seem to show AEN and BAX as the main targets in the induction of apoptosis in response to 2AA exposure, though p53, MDM2, and JUN may play supporting roles. Conclusion: Dose-dependent increases in mRNA expression were observed in all genes except Casp3. BAX was very highly expressed in the HD rats belonging to the 2-week exposure group. This trend was not observed in the animals treated for 4 weeks. Instead, AEN was rather very highly expressed in the liver of the MD animals that were treated with 2AA for 28 days.


2-aminoanthracene, apoptosis enhancing nuclease, apoptosis, Bcl2-associated X protein, F344, quantitative real‑time polymerase chain reaction

Full Text:


Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for polycyclic aromatic hydrocarbons (PAHs). US Department of Health and Human Services, Public Health Service. Atlanta; 1995. Availble from: http://www.atsdr. cdc.gov/ToxProfiles/tp69.pdf [Last accessed on 8/2/2013].

Gato WE, Hales DB, Means JC. Hepatic gene expression analysis of 2-aminoanthracene exposed Fisher-344 Rats reveal patterns indicative of liver carcinoma and type-2 diabetes. J Toxicol Sci 2012;37:1001-16.

Shimada T, Murayama N, Yamazaki H, Tanaka K, Takenaka S, Komori M, et al. Metabolic activation of polycyclic aromatic hydrocarbons and aryl and heterocyclic amines by human cytochromes P450 2A13 and 2A6. Chem Res Toxicol 2013.

Hatch FT, Knize MG, Colvin ME. Extended quantitative structureactivity relationships for 80 aromatic and heterocyclic amines: Structural, electronic, and hydropathic factors affecting mutagenic potency. Environ Mol Mutagen 2001;38:268-91.

Khlifi R, Messaoud O, Rebai A, Hamza-Chaffai A. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: Susceptibility to head and neck cancers. Biomed Res Int 2013;2013:582768.

Serafimova R, Todorov M, Pavlov T, Kotov S, Jacob E, Aptula A, et al. Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model. Chem Res Toxicol 2007;20:662-76.

So M, Hvastkovs EG, Bajrami B, Schenkman JB and Rusling JF. Electrochemical genotoxicity screening for arylamines bioactivated by N-acetyltransferase. Anal. Chem. 2008;80:1192-1200

Gato WE, Means JC. Pancreatic gene expression altered following dietary exposure to 2-Aminoanthracene: Links to diabetogenic activity. J Pharmacol Toxicol 2011;6:234-48.

Gato WE, Jay Means JC. Exploring transcriptional relationships within fisher-344 rats exposed to 2-aminoanthracene using VisANT network modeling and gene ontology tools. Res J Environ Toxicol 2011;5:251-65.

Huang X, Lu Z, Lv Z, Yu T, Yang P, Shen Y, et al. The Fas/Fas ligand death receptor pathway contributes to phenylalanine-induced apoptosis in cortical neurons. PLoS One 2013;8:e71553.

Kerr JF, Wyliie AH, Currie AR. Apoptosis: A basic phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.

Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.

Mukherjee JJ, Kumar S, Gocinski R, Williams J. Phenolic fraction of tobacco smoke inhibits BPDE-induced apoptosis response and potentiates cell transformation: Role of attenuation of p53 response. Chem Res Toxicol 2011;24:698-705.

Renehan AG, Booth C, Potten CS. What is apoptosis and why is it important? BMJ 2001;322:1536-8.

Boudreau MD, Taylor HW, Baker DG, Means JC. Dietary exposure to 2-aminoanthracene induces morphological and immunocytochemical changes in pancreatic tissues of Fisher-344 rats. Toxicol Sci 2006;93:50-61.

Qiagen Group. RNeasy® Mini Handbook. Valencia: Qiagen; 2011.

Bio-Rad Laboratories Inc., Experion™ RNA StdSens Analysis Kit; iScript one-step RT-PCR kit; SsoFast™ EvaGreen® Supermix. Hercules.

GenScript TUNEL Apoptosis Detection biotin-labeled POD Kit from GenScript (L00297), Piscataway; 2011.

Alvero AB, Mor G. Rapid assay for cell death. Promega Notes 2004;87:15-7.

Promega Technical Bulletin () Caspase-Glo 3/7 Assay. Madison: Promega Corporation; 2011.

Liu D, Li C, Chen Y, Burnett C, Liu XY, Downs S, et al. Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. J Biol Chem 2004;279:48434-42.

He B, Lu N, Zhou Z. Cellular and nuclear degradation during apoptosis. Curr Opin Cell Biol 2009;21:900-12.

Lee JH, Koh YA, Cho CK, Lee SJ, Lee YS, Bae S. Identification of a novel ionizing radiation-induced nuclease, AEN and its functional characterization in apoptosis. Biochem Biophys Res Commun 2005;337:39-47.

Rustemeyer SM, Lamberson WR, Ledoux DR, Wells K, Austin KJ, Cammack KM. Effects of dietary aflatoxin on the hepatic expression of apoptosis genes in growing barrows. J Anim Sci 2011;89:916-25.

Suenaga K, Takasawa H, Watanabe T, Wako Y, Suzuki T, Hamada S, et al. Differential gene expression profiling between genotoxic and non-genotoxichepatocarcinogens in young rat liver determined by quantitative real-time PCR and principal component analysis. Mutat Res 2013;751:73-83.

Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35:495-516.

Kawase T, Ichikawa H, Ohta T, Nozaki N, Tashiro F, Ohki R, et al. p53 target gene AEN is a nuclear exonuclease required for p53dependent apoptosis. Oncogene 2008;27:3797-810.

Kwak H-B, Effects of aging and exercise training on apoptosis in the heart. J Exerc Rehabil. 2013; 9:212-219

Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WM, et al. Caspase-3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006;311:847-51.

Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis.

Cell Death Differ 1999;6:99-104.

Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001;276:7320-6.

Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspase: A review. Clin Cancer Res 2005;11:3155-62.

Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, Kieser A, et al. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005;105:3263-9.

Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003;423:456-61.

Xin M and Deng X. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J Biol Chem 2006;281:18859-67.

Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.

Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121-32.

Thomadaki H, Scorilas A. Bcl2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006;43:1-67.

Bossy-Wetzel E, Bakiri L, Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J 1997;16:1695-709.

Lee SY, Yoon J, Lee HS, Hwang YS, Cha SW, Jeong CH, et al. The function of heterodimeric AP-1 comprised of c-Jun and c-Fos in activin mediated Spemann organizer gene expression. PLoS One 2011;6:e21796.

Poindessous-Jazat V, Augery-Bourget A, Robert-Lezenes J. C-Jun modulates apoptosis but not terminal cell differentiation in murine erythroleukemia cells. Leukemia 2002;16:233-43.

Wang R, Liu J, Huang C, Qian Q, Li Q, Liu X. Effects of acrylamide on the protein epxressions of c-fos and c-jun proto-oncogenes in cell L-02. Wei Sheng Yan Jiu 2010;39:183-6.

Yu RA, He LF, Chen XM. Effects of cadmium on hepatocellular DNA damage, proto-oncogene expression and apoptosis in rats. Biomed Environ Sci 2007;20:146-53.

Zhou F, Medh RD, Zhan W, Ansari NH, Thompson EB. The delayed induction of c-jun in apoptotic human leukemic lympohoblasts is primarily transcriptional. J Steroid Biochem Mol Biol 2000;75:91-9.

Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 2002;12:53-9.

Momand J, Wu HH, Dasgupta G. MDM2--master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.

Shangary S, Wang S. Small-molecule inhibitors of the Mdm2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41.

Thomasova D, Mulay SR, Bruns H, Ander HJ. p53-independent roles of Mdm2 in NF-KB signaling: Implications for cancer therapy, wound healing and autoimmune diseases. Neoplasia 2012;14:1097-101.

Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000;60:6788-93.

Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996;10:1054-72.

Vousden KH. Activation of the p53 suppressor protein. Biochim Biophys Acta 2002;1602:47-59.

Hopker K, Reinhardt HC. p53-regulating pathways as targets for personalized cancer therapy. Dtsch Med Wochenschr 2013;138:82-6.


  • There are currently no refbacks.